



EOS imaging Announces Sales Force Structure in Asia

New Distribution Agreements and Regional Office Pave Way for Further Commercialization of EOS® 3D Imaging System

Paris, May 22, 2013 – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced its expansion in Asia, including multiple new regional distribution agreements and the recruitment of a Regional Sales Manager, who will be based in a new Singapore office.

Marie Meynadier, CEO of EOS imaging, said, “This is an important growth milestone for the Company, as EOS now has reach into a significant portion of the imaging market in Asia. To date, we have completed distribution agreements, training and first hospital visits with partners covering eight Asian countries totalling 26% of the worldwide market for medical imaging¹. We will be devoting increasing attention and resources to our efforts in Asia as we look to capitalize on the rising demand for our technology in this area.”

Asia is a growing market in medical imaging, representing an estimated 41% of the worldwide market¹ with a strong demand for advanced imaging modalities fueled by infrastructure investments by regional governments¹. EOS recently established new distribution agreements in Japan, Korea, Taiwan, Thailand, Malaysia and Indonesia. These are in addition to its existing agreements in Hong Kong and Singapore, where the first EOS® Imaging System in Asia was installed in September 2012. EOS imaging has also appointed a Regional Sales Manager and opened an office in Singapore to oversee its growing regional sales network.

The EOS System is the only full body, low dose 3D orthopaedic imaging system and is currently available in 14 countries. For more information, please visit www.eos-imaging.com.

About EOS imaging:

EOS imaging designs develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of over 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group employed 63 people including an R&D team of 23 engineers, and posted 2012 consolidated revenue of €9.42 million. The Group is based in Paris and holds a United States subsidiary in Cambridge (Massachusetts) and offices in Montreal (Canada) and Germany.

For further information, please visit our website at www.eos-imaging.com.

**EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI**



Next update: half year 2013 revenues: July 17, 2013 after market close

Contacts:

Anne Renevot
CFO
Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)
Press relations
Ph: 646-536-7012
lcook@theruthgroup.com

¹ Frost & Sullivan. Global Trends and Transitions Shaping the Future of Medical Imaging Equipment. April 2013